PA8655401A1 - Nueva composicion farmaceutica que contiene por lo menos un derivado de dolastatina-10 - Google Patents

Nueva composicion farmaceutica que contiene por lo menos un derivado de dolastatina-10

Info

Publication number
PA8655401A1
PA8655401A1 PA20058655401A PA8655401A PA8655401A1 PA 8655401 A1 PA8655401 A1 PA 8655401A1 PA 20058655401 A PA20058655401 A PA 20058655401A PA 8655401 A PA8655401 A PA 8655401A PA 8655401 A1 PA8655401 A1 PA 8655401A1
Authority
PA
Panama
Prior art keywords
pharmaceutical composition
dolastatin
derivative
new pharmaceutical
cisplatino
Prior art date
Application number
PA20058655401A
Other languages
English (en)
Inventor
Yuko Aoki
Masanori Miwa
Fumie Sawamura
Hiromi Tanimura
Toshikazu Yamazaki
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8655401A1 publication Critical patent/PA8655401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA, QUE CONTIENE POR LO MENOS UN COMPUESTO DE LA FORMULA (I) EN COMBINACION CON LA CAPECITABINA, EL TRASTUZUMAB, EL PERTUZUMAB, EL CISPLATINO O EL IRINOTECAN PARA LA ADMINISTRACION SIMULTANEA, SUCESIVA O SEPARADA EN EL TRATAMIENTO DEL CANCER.
PA20058655401A 2004-12-13 2005-12-12 Nueva composicion farmaceutica que contiene por lo menos un derivado de dolastatina-10 PA8655401A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106522 2004-12-13
EP05100866 2005-02-08

Publications (1)

Publication Number Publication Date
PA8655401A1 true PA8655401A1 (es) 2006-08-03

Family

ID=36113901

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058655401A PA8655401A1 (es) 2004-12-13 2005-12-12 Nueva composicion farmaceutica que contiene por lo menos un derivado de dolastatina-10

Country Status (15)

Country Link
US (1) US20060292158A1 (es)
EP (1) EP1827603A2 (es)
JP (1) JP2008523002A (es)
KR (1) KR20070086123A (es)
AR (1) AR052046A1 (es)
AU (1) AU2005315912A1 (es)
BR (1) BRPI0519023A2 (es)
CA (1) CA2590431A1 (es)
GT (1) GT200500364A (es)
MX (1) MX2007006430A (es)
PA (1) PA8655401A1 (es)
PE (1) PE20060747A1 (es)
RU (1) RU2007126358A (es)
TW (1) TW200635609A (es)
WO (1) WO2006063707A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200034B2 (en) 2011-03-16 2015-12-01 Council Of Scientific & Industrial Research Oligopeptides and process for preparation thereof
MX368259B (es) 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4287523B2 (ja) * 1998-12-28 2009-07-01 あすか製薬株式会社 抗腫瘍剤
EP2266607A3 (en) * 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
US6737409B2 (en) * 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione

Also Published As

Publication number Publication date
EP1827603A2 (en) 2007-09-05
CA2590431A1 (en) 2006-06-22
MX2007006430A (es) 2007-07-19
WO2006063707A2 (en) 2006-06-22
GT200500364A (es) 2006-08-02
KR20070086123A (ko) 2007-08-27
PE20060747A1 (es) 2006-09-01
US20060292158A1 (en) 2006-12-28
JP2008523002A (ja) 2008-07-03
RU2007126358A (ru) 2009-01-20
BRPI0519023A2 (pt) 2008-12-23
AR052046A1 (es) 2007-02-28
TW200635609A (en) 2006-10-16
WO2006063707A3 (en) 2006-10-26
AU2005315912A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
PA8740901A1 (es) Compuestos organicos
MX2009011533A (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
CO6341574A2 (es) Composiciones de antagonistas dl pd-1 y metodos de uso
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
DOP2010000141A (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
UY32820A (es) Composiciones dermatologicas de antagonistas del receptor dp2
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
CR11290A (es) Derivados de ciclopropilamida
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CL2008000254A1 (es) Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.